Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perjeta + Docetaxel in Advanced Solid Tumors
NCT02490475Phase 1Completed
- Sponsor
- Roche
- Start
- Feb 2004
- Primary completion
- Apr 2006
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of pertuzumab in solid tumor (3 arms), sponsored by Roche. Primary endpoint: Maximum Tolerated Dose. Started Feb 2004; status: completed.
02
Drugs
pertuzumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02490475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02490475.